• Oncopeptides’ Q2 2026 earnings call drew CEO Sofia Heigis, CFO Henrik Bergentoft, IR director David Augustsson, Redeye’s Richard Ramanius.
• Net sales reached SEK 31.1 million, up 62%; cash totaled SEK 158 million following a March rights issue adding SEK 167 million.
• EMA Type II variation filed to move Pepaxti into third-line multiple myeloma; CHMP opinion expected September–November.
• Management expects first Salus-partnered Central and Eastern Europe sales in 2027; Slovenia list price secured, negotiations ongoing.
• U.S. is not a current priority; Japan partnering talks widened beyond an exclusive candidate due to delays; cash-flow positivity still targeted in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.